Business Description
Autolus Therapeutics PLC
NAICS : 325412
SIC : 2834
191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Compare
Compare
Traded in other countries / regions
6A3A.Germany
•
AUTL.USA
Description
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 12.58 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.7 | |||||
Beneish M-Score | -2.26 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -7 | |||||
3-Year EPS without NRI Growth Rate | -11.5 | |||||
3-Year FCF Growth Rate | -10.6 | |||||
3-Year Book Growth Rate | -18.5 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62.64 | |||||
9-Day RSI | 64.73 | |||||
14-Day RSI | 63.36 | |||||
6-1 Month Momentum % | -32.18 | |||||
12-1 Month Momentum % | -48.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.29 | |||||
Quick Ratio | 7.29 | |||||
Cash Ratio | 6.09 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -31.3 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -21344.59 | |||||
Net Margin % | -18806.56 | |||||
ROE % | -58.3 | |||||
ROA % | -45.24 | |||||
ROIC % | -174.36 | |||||
ROC (Joel Greenblatt) % | -342.65 | |||||
ROCE % | -56.77 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 328.84 | |||||
PB Ratio | 1.37 | |||||
Price-to-Tangible-Book | 1.42 | |||||
EV-to-EBIT | -0.57 | |||||
EV-to-EBITDA | -0.62 | |||||
EV-to-Revenue | 123.82 | |||||
EV-to-Forward-Revenue | 765.86 | |||||
EV-to-FCF | -1.06 | |||||
Price-to-Net-Current-Asset-Value | 1.91 | |||||
Price-to-Net-Cash | 2.59 | |||||
Earnings Yield (Greenblatt) % | -174.47 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:AUTL
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.823 | ||
EPS (TTM) ($) | -1.85 | ||
Beta | 1.73 | ||
Volatility % | 57.25 | ||
14-Day RSI | 63.36 | ||
14-Day ATR ($) | 0.279714 | ||
20-Day SMA ($) | 3.1915 | ||
12-1 Month Momentum % | -48.78 | ||
52-Week Range ($) | 1.96 - 7.9 | ||
Shares Outstanding (Mil) | 90.91 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Autolus Therapeutics PLC Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |